A Gastric Cancer Peptide GX1-Modified Nano-Lipid Carriers Encapsulating Paclitaxel: Design and Evaluation of Anti-Tumor Activity

References

• SiegelRL, MillerKD, JemalA. Cancer statistics. CA Cancer J Clin. 2017;67(1):7–30. doi:10.3322/caac.2138728055103
   PubMed Web of Science ®Google Scholar
• DigkliaA, WagnerAD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016;22(8):2403–2414. doi:10.3748/wjg.v22.i8.240326937129
   PubMed Web of Science ®Google Scholar
• OhSC. Update of adjuvant chemotherapy for resected gastric cancer. J Gastric Cancer. 2012;12(1):3–6. doi:10.5230/jgc.2012.12.1.322500257
   PubMedGoogle Scholar
• SchwarzRE, SmithDD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317–328. doi:10.1245/s10434-006-9218-217094022
   PubMed Web of Science ®Google Scholar
• JemalA, BrayF, CenterMM, FerlayJ, WardE, FormanD. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90. doi:10.3322/caac.2010721296855
   PubMed Web of Science ®Google Scholar
• ChenW, ZhengR, BaadePD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• MadenCH, GomesJ, SchwarzQ, DavidsonK, TinkerA, RuhrbergC. NRP1 and NRP2 cooperate to regulate gangliogenesis, axon guidance and target innervation in the sympathetic nervous system. Dev Biol. 2012;369(2):277–285. doi:10.1016/j.ydbio.2012.06.02622790009
   PubMed Web of Science ®Google Scholar
• NishikawaK, AoyamaT, ObaMS, et al. The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: analyses of pooled data from two Phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). J Cancer. 2018;9(10):1725–1730. doi:10.7150/jca.2473329805697
   PubMed Web of Science ®Google Scholar
• LeeJH, KimJG, JungHK, et al. Clinical practice guidelines for gastric cancer in Korea: an evidence-based approach. J Gastric Cancer. 2014;14(2):87–104. doi:10.5230/jgc.2014.14.2.8725061536
   PubMedGoogle Scholar
• XinJ, WangS, WangB, et al. AlPcS4-PDT for gastric cancer therapy using gold nanorod, cationic liposome, and Pluronic((R)) F127 nanomicellar drug carriers. Int J Nanomed. 2018;13:2017–2036. doi:10.2147/IJN.S154054
   PubMed Web of Science ®Google Scholar
• KimHS, KimJH, KimJW, KimBC. Chemotherapy in elderly patients with gastric cancer. J Cancer. 2016;7(1):88–94. doi:10.7150/jca.1324826722364
   PubMed Web of Science ®Google Scholar
• FarranB, MullerS, MontenegroRC. Gastric cancer management: kinases as a target therapy. Clin Exp Pharmacol Physiol. 2017;44(6):613–622. doi:10.1111/1440-1681.1274328271563
   PubMed Web of Science ®Google Scholar
• FolkmanJ. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi:10.1056/NEJM1971111828521084938153
   PubMed Web of Science ®Google Scholar
• YangT, WangY, LiZ, et al. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 2012;8(1):81–92. doi:10.1016/j.nano.2011.05.00321664295
   PubMed Web of Science ®Google Scholar
• ZhiM, WuKC, DongL, et al. Characterization of a specific phage-displayed peptide binding to vasculature of human gastric cancer. Cancer Biol Ther. 2004;3(12):1232–1235. doi:10.4161/cbt.3.12.122315492500
   PubMed Web of Science ®Google Scholar
• HuiX, HanY, LiangS, et al. Specific targeting of the vasculature of gastric cancer by a new tumor-homing peptide CGNSNPKSC. J Control Release. 2008;131(2):86–93. doi:10.1016/j.jconrel.2008.07.02418700158
   PubMed Web of Science ®Google Scholar
• ChenK, SunX, NiuG, et al. Evaluation of 64Cu labeled GX1: a phage display peptide probe for PET imaging of tumor vasculature. Mol Imaging Biol. 2012;14(1):96–105. doi:10.1007/s11307-011-0479-121360213
   PubMed Web of Science ®Google Scholar
• DuY, ZhangQ, JingL, et al. GX1-conjugated poly(lactic acid) nanoparticles encapsulating endostar for improved in vivo anticolorectal cancer treatment. Int J Nanomed. 2015;10:3791–3802. doi:10.2147/IJN.S82029
   PubMed Web of Science ®Google Scholar
• XiongD, LiuZ, BianT, et al. GX1-mediated anionic liposomes carrying adenoviral vectors for enhanced inhibition of gastric cancer vascular endothelial cells. Int J Pharm. 2015;496(2):699–708. doi:10.1016/j.ijpharm.2015.11.01926570987
   PubMed Web of Science ®Google Scholar
• ZhangE, XingR, LiuS, et al. Vascular targeted chitosan-derived nanoparticles as docetaxel carriers for gastric cancer therapy. Int J Biol Macromol. 2019;126:662–672. doi:10.1016/j.ijbiomac.2018.12.26230599159
   PubMed Web of Science ®Google Scholar
• RazaK, ShareefMA, SingalP, SharmaG, NegiP, KatareOP. Lipid-based capsaicin-loaded nano-colloidal biocompatible topical carriers with enhanced analgesic potential and decreased dermal irritation. J Liposome Res. 2014;24(4):290–296. doi:10.3109/08982104.2014.91131424766639
   PubMed Web of Science ®Google Scholar
• KamalyN, XiaoZ, ValenciaPM, Radovic-MorenoAF, FarokhzadOC. Targeted polymeric therapeutic nanoparticles: design Development and Clinical Translation. Chem Soc Rev. 2012;41(7):2971–3010.22388185
   PubMed Web of Science ®Google Scholar
• BareschinoMA, SchettinoC, RossiA, et al. Treatment of advanced non small cell lung cancer. J Thorac Dis. 2011;3(2):122–133. doi:10.3978/j.issn.2072-1439.2010.12.0822263075
   PubMedGoogle Scholar
• ChenCC, TsaiTH, HuangZR, FangJY. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics. Eur J Pharm Biopharm. 2010;74(3):474–482. doi:10.1016/j.ejpb.2009.12.00820060469
   PubMed Web of Science ®Google Scholar
• RyuMH, RyooBY, KimTW, et al. A phase I/IIa study of DHP107, a novel oral paclitaxel formulation, in patients with advanced solid tumors or gastric cancer. Oncologist. 2017;22(2):129–e8. doi:10.1634/theoncologist.2016-027328196905
   PubMed Web of Science ®Google Scholar
• QianJ, QianY, WangJ, et al. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther. 2016;10:241–258. doi:10.2147/DDDT.S88743
   PubMed Web of Science ®Google Scholar
• WangSQ, WangC, ChangLM, et al. Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway. Oncotarget. 2016;7(45):72990–73002. doi:10.18632/oncotarget.1216627659528
   PubMedGoogle Scholar
• SasakiY, NishinaT, YasuiH, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014;105(7):812–817. doi:10.1111/cas.1241924716542
   PubMed Web of Science ®Google Scholar
• ZhangC, AwasthiN, SchwarzMA, HinzS, SchwarzRE. Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer. PLoS One. 2013;8(2):e58037. doi:10.1371/journal.pone.005803723460921
   PubMed Web of Science ®Google Scholar
• OzcelikB, TurkyilmazC, OzgunMT, et al. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril. 2010;93(5):1609–1614. doi:10.1016/j.fertnstert.2009.02.05419339002
   PubMed Web of Science ®Google Scholar
• BarbutiAM, ChenZS. paclitaxel through the ages of anticancer therapy: exploring its role in chemoresistance and radiation therapy. Cancers. 2015;7(4):2360–2371. doi:10.3390/cancers704089726633515
   PubMed Web of Science ®Google Scholar
• SonnenblickA, EleyanF, PeretzT, et al. Gemcitabine in combination with paclitaxel for advanced soft-tissue sarcomas. Mol Clin Oncol. 2015;3(4):829–832. doi:10.3892/mco.2015.54526171190
   PubMedGoogle Scholar
• NeijtJP, EngelholmSA, TuxenMK, et al. Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084–3092. doi:10.1200/JCO.2000.18.17.308410963636
   PubMed Web of Science ®Google Scholar
• MaoY, ZhangY, LuoZ, et al. Synthesis, biological evaluation and low-toxic formulation development of glycosylated paclitaxel prodrugs. Molecules. 2018;23(12):3211. doi:10.3390/molecules23123211
   PubMed Web of Science ®Google Scholar
• DingY, JiaY, LuC, et al. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008). Biomed Pharmacother. 2012;66(4):318–321. doi:10.1016/j.biopha.2012.01.00122397757
   PubMed Web of Science ®Google Scholar
• ZhouL, LuoW. Vascular endothelial growth factor-targeted paclitaxel-loaded liposome microbubbles and inhibition of human epidermoid-2 cell proliferation. Head Neck. 2017;39(4):656–661. doi:10.1002/hed.2464828106938
   PubMed Web of Science ®Google Scholar
• WangQ, LiC, RenT, et al. Poly(vinyl methyl ether/maleic anhydride)-doped PEG-PLA nanoparticles for oral paclitaxel delivery to improve bioadhesive efficiency. Mol Pharm. 2017;14(10):3598–3608. doi:10.1021/acs.molpharmaceut.7b0061228892400
   PubMed Web of Science ®Google Scholar
• LiuJ, ChengH, HanL, et al. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles. Drug Des Devel Ther. 2018;12:3199–3209. doi:10.2147/DDDT.S172199
   PubMed Web of Science ®Google Scholar
• JoshiMD, MullerRH. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm. 2009;71(2):161–172. doi:10.1016/j.ejpb.2008.09.00318824097
   PubMed Web of Science ®Google Scholar
• BialeckaM. [The effect of bioflavonoids and lecithin on the course of experimental atherosclerosis in rabbits]. Ann Acad Med Stetin. 1997;43:41–56. Polish.9471922
   PubMedGoogle Scholar
• WuL, DingJ. In vitro degradation of three-dimensional porous poly(D,L-lactide-co-glycolide) scaffolds for tissue engineering. Biomaterials. 2004;25(27):5821–5830. doi:10.1016/j.biomaterials.2004.01.03815172494
   PubMed Web of Science ®Google Scholar
• RezazadehM, EmamiJ, HassanzadehF, SadeghiH, RostamiM, MohammadkhaniH. Targeted nanostructured lipid carriers for delivery of paclitaxel to cancer cells: preparation, characterization, and cell toxicity. Curr Drug Deliv. 2017;14(8):1189–1200. doi:10.2174/156720181466617050314364628472908
   PubMed Web of Science ®Google Scholar
• ZhaoC, FanT, YangY, et al. Preparation, macrophages targeting delivery and anti-inflammatory study of pentapeptide grafted nanostructured lipid carriers. Int J Pharm. 2013;450(1–2):11–20. doi:10.1016/j.ijpharm.2013.04.03023612355
   PubMed Web of Science ®Google Scholar
• ZhaoC, LiuY, FanT, et al. A novel strategy for encapsulating poorly soluble drug into nanostructured lipid carriers for intravenous administration. Pharm Dev Technol. 2012;17(4):443–456. doi:10.3109/10837450.2010.54641121222507
   PubMed Web of Science ®Google Scholar
• JianY, BuW, ChuJ, et al. Preparation and characterization of gastric cancer vasculature targeted peptide GX1 mediatednanostructured Iipid carriers Ioaded with pacIitaxeI. Chinese J New Drugs. 2018;27(18):54–61.
   Google Scholar
• ChenC, FanT, JinY, et al. Orally delivered salmon calcitonin-loaded solid lipid nanoparticles prepared by micelle-double emulsion method via the combined use of different solid lipids. Nanomedicine. 2013;8(7):1085–1100. doi:10.2217/nnm.12.14123075315
   PubMed Web of Science ®Google Scholar
• AccardoA, MannucciS, NicolatoE, et al. Easy formulation of liposomal doxorubicin modified with a bombesin peptide analogue for selective targeting of GRP receptors overexpressed by cancer cells. Drug Deliv Transl Res. 2019;9(1):215–226. doi:10.1007/s13346-018-00606-x30569349
   PubMed Web of Science ®Google Scholar
• NiYJ, LuJ, ZhouHM. Propofol suppresses proliferation, migration and invasion of gastric cancer cells via regulating miR-29/MMP-2 axis. Eur Rev Med Pharmacol Sci. 2019;23(19):8606–8615. doi:10.26355/eurrev_201910_1917731646594
   PubMed Web of Science ®Google Scholar
• WangZ, YuK, HuY, et al. Schisantherin A induces cell apoptosis through ROS/JNK signaling pathway in human gastric cancer cells. Biochem Pharmacol. 2019;113673.31629709
   PubMed Web of Science ®Google Scholar
• ChenB, CaoS, ZhangY, et al. A novel peptide (GX1) homing to gastric cancer vasculature inhibits angiogenesis and cooperates with TNF alpha in anti-tumor therapy. BMC Cell Biol. 2009;10:63. doi:10.1186/1471-2121-10-6319740430
   PubMed Web of Science ®Google Scholar
• ZhangJ, ZhangP, ZouQ, et al. Co-delivery of gemcitabine and paclitaxel in cRGD-modified long circulating nanoparticles with asymmetric lipid layers for breast cancer treatment. Molecules. 2018;23(11).
   Web of Science ®Google Scholar
• Kukowska-LatalloJF, CandidoKA, CaoZ, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65(12):5317–5324. doi:10.1158/0008-5472.CAN-04-392115958579
   PubMed Web of Science ®Google Scholar